Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis

被引:1
|
作者
Hayashi, Hironori [1 ]
Amaya, Koji [1 ]
Tokoro, Tomokazu [1 ]
Mori, Kosuke [1 ]
Takenaka, Shunsuke [1 ]
Sugimoto, Yuya [1 ]
Kitano, Yuto [1 ]
Kurata, Toru [1 ]
Kawai, Shunsuke [1 ]
Hirose, Atsushi [1 ]
Tsukada, Tomoya [1 ]
Kaji, Masahide [1 ]
Shimizu, Koichi [2 ]
Maeda, Kiichi [1 ]
机构
[1] Toyama Prefectural Cent Hosp, Dept Surg, 2-2-78 Nishi Nagae, Toyama 9308550, Japan
[2] Kaga Med Ctr, Dept Surg, Kaga, Ishikawa 9228522, Japan
关键词
cancer genomics; epidemiology; multiple primary malignancies; pancreatic ductal adenocarcinoma; prognosis; surgical treatment; CANCER PATIENTS; ORGANS; IMPACT;
D O I
10.3892/mco.2021.2.335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with pancreatic ductal adenocarcinoma (PDAC) that have a history of other primary malignancies are not well documented. The current study therefore aimed to evaluate the dinicopathological characteristics of patients with PDAC with or without a history of other primary malignancies. A total of 102 patients with surgically treated PDAC that presented with or without a history of other primary malignancies were retrospectively analyzed. A total of 25 patients (24.5%) had a history of other primary malignancies (age, with history of other primary malignancy vs. without, 74.2 vs. 68.9 years; P=0.005) and the reason for consultation (P<0.001) differed significantly between the groups with a history of other primary malignancies [FloM(+)] and without a history of other primary malignancies [HOMO]. Incidental indications during malignancy follow-up was the most common reason for the diagnosis of PDAC in the HoM(+) group. Conversely, there were no significant differences in the resectability (P=0.645), complete resection rate (P=0.774) and final stage (P=0.474) between the two groups. Disease-free survival was also not significantly different between the two groups (P=0.184). However, overall survival was significantly poorer in the HoM(+) group compared with the HoM(-) group (P=0.003). A history of other primary malignancies was also an independent predictor of poor overall survival (hazard ratio, 2.416; 95% confidence interval, 1.324-4.406; P=0.004). In conclusion, patients with PDAC and a history of other primary malignancies had significantly poorer overall survival than their counterparts, despite no differences in disease-free survival.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Clinical features and outcomes of colloid carcinoma of pancreas compared to pancreatic ductal adenocarcinoma.
    Khalil, Lana
    Zakka, Katerina Mary
    Jiang, Renjian
    Penely, Mckenna
    Alese, Olatunji B.
    Shaib, Walid Labib
    Wu, Christina
    Diab, Maria
    Behera, Madhusmita
    Reid, Michelle D.
    El-Rayes, Bassel F.
    Akce, Mehmet
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome
    Liudahl, Shannon M.
    Betts, Courtney B.
    Sivagnanam, Shamilene
    Morales-Oyarvide, Vicente
    da Silva, Annacarolina
    Yuan, Chen
    Hwang, Samuel
    Grossblatt-Wait, Alison
    Leis, Kenna R.
    Larson, William
    Lavoie, Meghan B.
    Robinson, Padraic
    Costa, Andressa Dias
    Vayrynen, Sara A.
    Clancy, Thomas E.
    Rubinson, Douglas A.
    Link, Jason
    Keith, Dove
    Horton, Wesley
    Tempero, Margaret A.
    Vonderheide, Robert H.
    Jaffee, Elizabeth M.
    Sheppard, Brett
    Goecks, Jeremy
    Sears, Rosalie C.
    Park, Byung S.
    Mori, Motomi
    Nowak, Jonathan A.
    Wolpin, Brian M.
    Coussens, Lisa M.
    CANCER DISCOVERY, 2021, 11 (08) : 2014 - 2031
  • [43] The impact of a history of cancer on pancreatic ductal adenocarcinoma survival
    He, Xingkang
    Li, Yue
    Su, Tingting
    Lai, Sanchuan
    Wu, Wenrui
    Chen, Luyi
    Si, Jianmin
    Sun, Leimin
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (06) : 888 - 894
  • [44] Role of primary cilium in pancreatic ductal adenocarcinoma (Review)
    Sabanovic, Berina
    Giulietti, Matteo
    Piva, Francesco
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 57 (05) : 1095 - 1102
  • [45] Challenges in genomic analysis of model systems and primary tumors of pancreatic ductal adenocarcinoma
    Hyun, Sangyeop
    Park, Daechan
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 : 4806 - 4815
  • [46] Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations
    Reiss, Kim A.
    Yu, Shun
    Judy, Renae
    Symecko, Heather
    Nathanson, Katherine L.
    Domchek, Susan M.
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 9
  • [47] Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation
    Yu, Shun
    Agarwal, Parul
    Mamtani, Ronac
    Symecko, Heather
    Spielman, Kelsey
    O'Hara, Mark
    O'Dwyer, Peter J.
    Schneider, Charles
    Teitelbaum, Ursina
    Nathanson, Katherine L.
    Domchek, Susan M.
    Reiss, Kim A.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 11
  • [48] Characterization of primary and metastatic pancreatic tumors in pancreatic ductal adenocarcinoma (PDAC)
    Martinez-Muniz, Andres E.
    Sivanand, Sharanya
    Vander Heiden, Matthew
    CANCER RESEARCH, 2019, 79 (13)
  • [49] Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter retrospective study
    Yamamoto, Tomohisa
    Shimokawa, Toshio
    Hayashi, Masamichi
    Mizuma, Masamichi
    Hirano, Katsuhisa
    Oba, Atsushi
    Asano, Toshimichi
    Miyato, Hideyo
    Yoshida, Makoto
    Matsumoto, Ippei
    Kawabata, Yasunari
    Sakamoto, Katsunori
    Motoi, Fuyuhiko
    Ishii, Shigeto
    Homma, Yuki
    Maehira, Hiromitsu
    Matsunaga, Yutaro
    Ikemoto, Tetsuya
    Nakamura, Masafumi
    Mataki, Yuko
    Notake, Tsuyoshi
    Akahoshi, Keiichi
    Takami, Hideki
    Yamaki, So
    Hashimoto, Daisuke
    Kimura, Yasutoshi
    Hirano, Satoshi
    Inoue, Yosuke
    Fujii, Tsutomu
    Unno, Michiaki
    Kodera, Yasuhiro
    Kitayama, Joji
    Satoi, Sohei
    Study Grp Pancreatic Ductal Adenocarcinoma Peritoneal Dissemination
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2025,
  • [50] Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
    Man Hung Choi
    Eline Mejlænder-Andersen
    Sophia Manueldas
    Khadija El Jellas
    Solrun J. Steine
    Kjersti Tjensvoll
    Hege Aase Sætran
    Stian Knappskog
    Dag Hoem
    Oddmund Nordgård
    Randi Hovland
    Anders Molven
    BMC Cancer, 19